Reaction

Chronic Myeloid Leukaemia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,568 reports · 47 co-occurring drugs

As of the last recalculation, Chronic Myeloid Leukaemia appears in 4,568 FAERS reports alongside 47 co-occurring drug terms. The strongest observed disproportionality signal is NILOTINIB (PRR 155.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Nilotinib	827	155.8	160.3
Imatinib	483	139.4	143.3
Imatinib Mesylate	443	80.0	81.3
Bosutinib	146	76.5	77.7
Dasatinib	297	38.9	39.2
Hydroxyurea	162	36.2	36.4
Bleomycin Sulfate	37	16.4	16.5
Romiplostim	24	7.3	7.3
Busulfan	22	6.4	6.4
Melphalan	26	5.2	5.2
Cytarabine	65	5.0	5.0
Tacrolimus Extended-Release Capsules	130	4.9	4.9
Tacrolimus Ointment 0.1%	129	4.8	4.8
Melphalan Hydrochloride	26	4.7	4.8
Azacitidine	28	4.3	4.3
Ruxolitinib	66	4.2	4.2
Tacrolimus	142	4.2	4.2
Methylprednisolone Acetate	7	4.0	4.0
Fludarabine Phosphate	32	3.7	3.7
Sirolimus	11	3.7	3.7
Mercaptopurine	14	3.7	3.7
Cyclophosphamide Injection, Solution	137	3.6	3.6
Cyclophosphamide	137	3.6	3.6
Cyclophosphamide For Injection	137	3.6	3.6
Etoposide	55	3.4	3.4
Eltrombopag Olamine	17	3.4	3.4
Allopurinol	112	3.3	3.3
Mycophenolate Mofetil	97	3.3	3.3
Mycophenolate Mofetil Hydrochloride	97	3.3	3.3
Azacitidine For	13	3.3	3.3
Fluorouracil Cream, 0.5%	46	2.8	2.8
Fluorouracil	46	2.7	2.7
Erythropoietin	12	2.7	2.7
Vincristine Sulfate	17	2.6	2.7
Deferasirox	15	2.6	2.6
Oxaliplatin	41	2.5	2.5
Prochlorperazine Maleate	5	2.5	2.5
Doxorubicin	48	2.5	2.5
Dorzolamide Hydrochloride And Timolol Maleate	4	2.3	2.3
Blinatumomab	5	2.2	2.2
Interferon Beta-1B	9	2.1	2.1
Irinotecan Hydrochloride	6	2.1	2.1
Bendamustine Hcl	7	2.1	2.1
Venetoclax	27	2.0	2.0
Ivacaftor	3	1.7	1.7
Axitinib	7	1.6	1.6
Ranitidine Hydrochloride	15	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.